JP2018502828A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018502828A5 JP2018502828A5 JP2017527368A JP2017527368A JP2018502828A5 JP 2018502828 A5 JP2018502828 A5 JP 2018502828A5 JP 2017527368 A JP2017527368 A JP 2017527368A JP 2017527368 A JP2017527368 A JP 2017527368A JP 2018502828 A5 JP2018502828 A5 JP 2018502828A5
- Authority
- JP
- Japan
- Prior art keywords
- mutations
- lung cancer
- aforementioned
- immune checkpoint
- synonymous
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2022129458A JP7550193B2 (ja) | 2014-11-21 | 2022-08-16 | Pd-1遮断による免疫療法の癌奏効の決定因子 |
| JP2024107117A JP2024125234A (ja) | 2014-11-21 | 2024-07-03 | Pd-1遮断による免疫療法の癌奏効の決定因子 |
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462083088P | 2014-11-21 | 2014-11-21 | |
| US62/083,088 | 2014-11-21 | ||
| US201562132381P | 2015-03-12 | 2015-03-12 | |
| US62/132,381 | 2015-03-12 | ||
| PCT/US2015/062208 WO2016081947A2 (en) | 2014-11-21 | 2015-11-23 | Determinants of cancer response to immunotherapy by pd-1 blockade |
Related Child Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020135853A Division JP2020196732A (ja) | 2014-11-21 | 2020-08-11 | Pd−1遮断による免疫療法の癌奏効の決定因子 |
| JP2022129458A Division JP7550193B2 (ja) | 2014-11-21 | 2022-08-16 | Pd-1遮断による免疫療法の癌奏効の決定因子 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2018502828A JP2018502828A (ja) | 2018-02-01 |
| JP2018502828A5 true JP2018502828A5 (cg-RX-API-DMAC7.html) | 2022-09-01 |
| JP7173733B2 JP7173733B2 (ja) | 2022-11-16 |
Family
ID=56014697
Family Applications (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017527368A Active JP7173733B2 (ja) | 2014-11-21 | 2015-11-23 | Pd-1遮断による免疫療法の癌奏効の決定因子 |
| JP2020135853A Withdrawn JP2020196732A (ja) | 2014-11-21 | 2020-08-11 | Pd−1遮断による免疫療法の癌奏効の決定因子 |
| JP2022129458A Active JP7550193B2 (ja) | 2014-11-21 | 2022-08-16 | Pd-1遮断による免疫療法の癌奏効の決定因子 |
| JP2024107117A Pending JP2024125234A (ja) | 2014-11-21 | 2024-07-03 | Pd-1遮断による免疫療法の癌奏効の決定因子 |
Family Applications After (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020135853A Withdrawn JP2020196732A (ja) | 2014-11-21 | 2020-08-11 | Pd−1遮断による免疫療法の癌奏効の決定因子 |
| JP2022129458A Active JP7550193B2 (ja) | 2014-11-21 | 2022-08-16 | Pd-1遮断による免疫療法の癌奏効の決定因子 |
| JP2024107117A Pending JP2024125234A (ja) | 2014-11-21 | 2024-07-03 | Pd-1遮断による免疫療法の癌奏効の決定因子 |
Country Status (8)
| Country | Link |
|---|---|
| US (3) | US20180291074A1 (cg-RX-API-DMAC7.html) |
| EP (2) | EP4393546A3 (cg-RX-API-DMAC7.html) |
| JP (4) | JP7173733B2 (cg-RX-API-DMAC7.html) |
| CN (2) | CN114672559A (cg-RX-API-DMAC7.html) |
| AU (3) | AU2015349644B2 (cg-RX-API-DMAC7.html) |
| HK (1) | HK1244440A1 (cg-RX-API-DMAC7.html) |
| MA (1) | MA40737A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2016081947A2 (cg-RX-API-DMAC7.html) |
Families Citing this family (57)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX356367B (es) | 2008-12-09 | 2018-05-25 | Genentech Inc | Anticuerpos anti-pd-l1 y su uso para mejorar la funcion de celulas t. |
| CR20160319A (es) | 2013-12-12 | 2016-11-08 | Jiangsu Hengrui Medicine Co | Anticuerpo pd-1, fragmento de union al antigeno de este y uso médico de este |
| HUE054012T2 (hu) | 2014-10-29 | 2021-08-30 | Five Prime Therapeutics Inc | Kombinációs terápia rák ellen |
| MA40737A (fr) | 2014-11-21 | 2017-07-04 | Memorial Sloan Kettering Cancer Center | Déterminants de la réponse d'un cancer à une immunothérapie par blocage de pd-1 |
| GB201516047D0 (en) | 2015-09-10 | 2015-10-28 | Cancer Rec Tech Ltd | Method |
| JP7114477B2 (ja) | 2015-12-16 | 2022-08-08 | グリットストーン バイオ インコーポレイテッド | 新生抗原の特定、製造、および使用 |
| JP2019505512A (ja) | 2016-01-08 | 2019-02-28 | バッシボディ アクスイェ セルスカプ | 治療用抗癌ネオエピトープワクチン |
| US11725247B2 (en) | 2016-02-29 | 2023-08-15 | Foundation Medicine, Inc. | Methods of treating cancer |
| WO2017151502A1 (en) | 2016-02-29 | 2017-09-08 | Genentech, Inc. | Therapeutic and diagnostic methods for cancer |
| JP6918816B2 (ja) * | 2016-03-01 | 2021-08-18 | ノース カロライナ ステート ユニバーシティ | マイクロニードルパッチ支援送達による強化されたがん免疫療法 |
| JP7147168B2 (ja) * | 2016-03-02 | 2022-10-05 | 東レ株式会社 | 免疫誘導剤 |
| KR102543118B1 (ko) | 2016-05-27 | 2023-06-14 | 아게누스 인코포레이티드 | 항-tim-3 항체 및 이의 사용 방법 |
| US11359017B2 (en) | 2016-07-01 | 2022-06-14 | Tohoku University | Method of altering an antibody-related adverse event based on SCD163 and/or CXCL5 levels |
| AU2017315468B2 (en) | 2016-08-25 | 2020-02-13 | Nantomics, Llc | Immunotherapy markers and uses therefor |
| KR102804118B1 (ko) * | 2016-10-06 | 2025-05-09 | 제넨테크, 인크. | 암에 대한 치료 및 진단 방법 |
| JP7295015B2 (ja) | 2016-10-07 | 2023-06-20 | オムニセック インコーポレイテッド | 個別化治療を決定するための方法 |
| WO2018132753A1 (en) * | 2017-01-13 | 2018-07-19 | Nantbio, Inc. | Validation of neoepitope-based treatment |
| US12331359B2 (en) | 2017-01-18 | 2025-06-17 | Michael Laessig | Neoantigens and uses thereof for treating cancer |
| MX2019009070A (es) | 2017-02-01 | 2019-10-30 | Modernatx Inc | Composiciones de arnm terapeuticas inmunomoduladoras que codifican peptidos de mutacion de oncogenes de activacion. |
| ES2885178T3 (es) * | 2017-02-06 | 2021-12-13 | Novartis Ag | Método para la predicción de respuesta a la inmunoterapia |
| US20190360051A1 (en) * | 2017-02-17 | 2019-11-28 | Stichting Vumc | Swarm intelligence-enhanced diagnosis and therapy selection for cancer using tumor- educated platelets |
| EP3601536A4 (en) * | 2017-03-20 | 2021-01-13 | Genocea Biosciences, Inc. | TREATMENT PROCEDURES |
| EP3601355A1 (en) * | 2017-03-31 | 2020-02-05 | Bristol-Myers Squibb Company | Methods of treating tumor |
| GB201710815D0 (en) * | 2017-07-05 | 2017-08-16 | Francis Crick Inst Ltd | Method |
| AU2018304458B2 (en) * | 2017-07-21 | 2021-12-09 | Foundation Medicine, Inc. | Therapeutic and diagnostic methods for cancer |
| US11899017B2 (en) * | 2017-07-28 | 2024-02-13 | Bristol-Myers Squibb Company | Predictive peripheral blood biomarker for checkpoint inhibitors |
| JP2020535119A (ja) * | 2017-09-13 | 2020-12-03 | ファイヴ プライム セラピューティクス インク | 膵臓がんの抗csf1rおよび抗pd−1抗体組合せ併用療法 |
| US20200268831A1 (en) * | 2017-09-15 | 2020-08-27 | The Texas A&M University System | Methods for enhancing immunotherapy in the treatment of cancer |
| AU2018338441B2 (en) | 2017-09-25 | 2025-08-14 | Memorial Sloan Kettering Cancer Center | Tumor mutational load and checkpoint immunotherapy |
| CA3076918A1 (en) * | 2017-10-02 | 2019-04-11 | Curematch, Inc. | Method of prediction of tumor-derived neo-peptide antigenicity and/or immunogenicity using mutational signature patterns |
| CN111465989B (zh) | 2017-10-10 | 2024-06-25 | 磨石生物公司 | 使用热点进行的新抗原鉴别 |
| WO2019075251A2 (en) * | 2017-10-12 | 2019-04-18 | Nantomics, Llc | CANCER SCORE FOR EVALUATION AND PREDICTION OF RESPONSE FROM BIOLOGICAL FLUIDS |
| EP3694884A1 (en) * | 2017-10-15 | 2020-08-19 | Bristol-Myers Squibb Company | Methods of treating tumor |
| EP3704268B1 (en) | 2017-11-03 | 2025-01-22 | Guardant Health, Inc. | Normalizing tumor mutation burden |
| WO2019095017A1 (en) * | 2017-11-17 | 2019-05-23 | Gmdx Co Pty Ltd | Systems and methods for predicting the efficacy of cancer therapy |
| AU2018373154B2 (en) | 2017-11-22 | 2025-08-07 | Seattle Project Corp. | Reducing junction epitope presentation for neoantigens |
| EP3622522A1 (en) | 2017-12-01 | 2020-03-18 | Illumina, Inc. | Methods and systems for determining somatic mutation clonality |
| EP3788173B1 (en) | 2018-05-03 | 2023-11-29 | F. Hoffmann-La Roche AG | Surrogate marker and method for tumor mutation burden measurement |
| BR112020022145A2 (pt) * | 2018-05-04 | 2021-01-26 | Merck Patent Gmbh | inibição combinada de pd-1/pd-l1, tgfbeta e dna-pk para o tratamento de câncer |
| CN120193081A (zh) | 2018-07-23 | 2025-06-24 | 夸登特健康公司 | 用于通过肿瘤分数和覆盖率调整肿瘤突变负荷的方法和系统 |
| US20210292851A1 (en) | 2018-07-27 | 2021-09-23 | Roche Sequencing Solutions, Inc. | Method of monitoring effectiveness of immunotherapy of cancer patients |
| WO2020045479A1 (ja) | 2018-08-29 | 2020-03-05 | 公益財団法人東京都医学総合研究所 | HGF-regulated tyrosine kinase substrate(HGS)を標的とした抗腫瘍剤 |
| JP7539367B2 (ja) | 2018-08-31 | 2024-08-23 | ガーダント ヘルス, インコーポレイテッド | 無細胞dnaにおけるマイクロサテライト不安定性の検出 |
| CA3120200A1 (en) | 2018-11-15 | 2020-05-22 | Personal Genome Diagnostics Inc. | Method of improving prediction of response for cancer patients treated with immunotherapy |
| WO2020121226A1 (en) * | 2018-12-12 | 2020-06-18 | Medimmune, Llc | Blood-based tumor mutation burden predicts overall survival in non-small cell lung cancer |
| EP3982954A4 (en) | 2019-06-14 | 2024-01-03 | The Trustees of Columbia University in the City of New York | NT5C2 INHIBITORS FOR THE TREATMENT OF CHEMOTHERAPY-RESISTANT ACUTE LYMPHOBLASTIC LEUKEMIA |
| EP4051314A4 (en) * | 2019-11-01 | 2023-12-06 | Memorial Sloan Kettering Cancer Center | Hla class i sequence divergence and cancer therapy |
| GB202003669D0 (en) * | 2020-03-13 | 2020-04-29 | Univ Oxford Innovation Ltd | Method for identifying neo-antigens |
| WO2021205027A1 (en) | 2020-04-09 | 2021-10-14 | Vaccibody As | Individualized therapeutic anticancer vaccine |
| EP4143345A1 (en) * | 2020-04-28 | 2023-03-08 | Genentech, Inc. | Methods and compositions for non-small cell lung cancer immunotherapy |
| US20230242992A1 (en) * | 2020-06-01 | 2023-08-03 | Gmdx Co Pty Ltd | Methods of predicting cancer progression |
| CN112309502B (zh) * | 2020-10-14 | 2024-09-20 | 深圳市新合生物医疗科技有限公司 | 一种计算肿瘤新抗原负荷的方法及系统 |
| CA3200667A1 (en) * | 2020-11-06 | 2022-05-12 | The General Hospital Corporation | Methods for characterizing biological samples |
| US20240238340A1 (en) * | 2021-05-03 | 2024-07-18 | Rutgers, The State University Of New Jersey | Immunotherapy for inflammatory bowel disease and/or cancer |
| CN113030475B (zh) * | 2021-05-25 | 2021-08-10 | 泛肽生物科技(浙江)有限公司 | 一种基于细胞线粒体质量评估的t细胞pd-1检测方法 |
| CN113355424B (zh) * | 2021-07-14 | 2022-03-25 | 江苏先声医学诊断有限公司 | Pcdh11x突变在预测非小细胞肺癌患者对免疫检查点抑制剂疗法敏感性中的应用 |
| CN122003713A (zh) | 2023-04-12 | 2026-05-08 | 西奈山伊坎医学院 | 用于选择个性化新抗原疫苗的计算方法 |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20040033497A1 (en) | 2002-08-13 | 2004-02-19 | Alarcon-Riquelme Marta E. | Polymorphisms of PD-1 |
| TWI477602B (zh) | 2006-02-09 | 2015-03-21 | Educational Foundation Jichi Medical Univ | Novel viral vector |
| US20110118298A1 (en) * | 2009-11-13 | 2011-05-19 | Infinity Pharmaceuticals, Inc. | Compositions, kits, and methods for identification, assessment, prevention, and therapy of cancer |
| GB201004551D0 (en) | 2010-03-19 | 2010-05-05 | Immatics Biotechnologies Gmbh | NOvel immunotherapy against several tumors including gastrointestinal and gastric cancer |
| JP6002659B2 (ja) * | 2010-04-13 | 2016-10-05 | セルデックス・セラピューティクス・インコーポレイテッド | ヒトcd27に結合する抗体およびその使用 |
| US9115402B2 (en) * | 2010-05-14 | 2015-08-25 | Dana-Farber Cancer Institute, Inc. | Compositions and methods of identifying tumor specific neoantigens |
| WO2013130748A1 (en) * | 2012-02-29 | 2013-09-06 | The Regents Of The University Of Michigan | Prostate cancer markers and uses thereof |
| PL2844282T3 (pl) | 2012-05-04 | 2019-11-29 | Pfizer | Antygeny związane z gruczołem krokowym i schematy immunoterapii oparte na szczepionce |
| US10501801B2 (en) | 2012-09-28 | 2019-12-10 | University Of Connecticut | Identification of tumor-protective epitopes for the treatment of cancers |
| SG11201605432RA (en) * | 2014-01-02 | 2016-07-28 | Sloan Kettering Inst Cancer | Determinants of cancer response to immunotherapy |
| KR20170080697A (ko) * | 2014-11-13 | 2017-07-10 | 더 존스 홉킨스 유니버시티 | 관문 차단 및 미소부수체 불안정성 |
| MA40737A (fr) | 2014-11-21 | 2017-07-04 | Memorial Sloan Kettering Cancer Center | Déterminants de la réponse d'un cancer à une immunothérapie par blocage de pd-1 |
| AU2018338441B2 (en) * | 2017-09-25 | 2025-08-14 | Memorial Sloan Kettering Cancer Center | Tumor mutational load and checkpoint immunotherapy |
-
2015
- 2015-11-22 MA MA040737A patent/MA40737A/fr unknown
- 2015-11-23 EP EP24157218.9A patent/EP4393546A3/en active Pending
- 2015-11-23 WO PCT/US2015/062208 patent/WO2016081947A2/en not_active Ceased
- 2015-11-23 US US15/528,385 patent/US20180291074A1/en not_active Abandoned
- 2015-11-23 AU AU2015349644A patent/AU2015349644B2/en active Active
- 2015-11-23 CN CN202210026426.9A patent/CN114672559A/zh active Pending
- 2015-11-23 CN CN201580073049.2A patent/CN107206064B/zh active Active
- 2015-11-23 JP JP2017527368A patent/JP7173733B2/ja active Active
- 2015-11-23 HK HK18103939.8A patent/HK1244440A1/zh unknown
- 2015-11-23 EP EP15861224.2A patent/EP3220950A4/en not_active Ceased
-
2019
- 2019-02-22 US US16/283,555 patent/US10993998B2/en active Active
-
2020
- 2020-08-11 JP JP2020135853A patent/JP2020196732A/ja not_active Withdrawn
-
2021
- 2021-03-15 US US17/202,173 patent/US12485162B2/en active Active
- 2021-08-09 AU AU2021215099A patent/AU2021215099A1/en not_active Abandoned
-
2022
- 2022-08-16 JP JP2022129458A patent/JP7550193B2/ja active Active
-
2024
- 2024-07-03 JP JP2024107117A patent/JP2024125234A/ja active Pending
- 2024-12-12 AU AU2024278364A patent/AU2024278364A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Succony et al. | Adenocarcinoma spectrum lesions of the lung: Detection, pathology and treatment strategies | |
| JP7497084B2 (ja) | がん治療の有効性を予測するためのシステムおよび方法 | |
| Perdomo et al. | Circulating tumor DNA detection in head and neck cancer: evaluation of two different detection approaches | |
| Liu et al. | Heterogeneity of PD-L1 expression among the different histological components and metastatic lymph nodes in patients with resected lung adenosquamous carcinoma | |
| Shay et al. | Bacteriome and mycobiome and bacteriome-mycobiome interactions in head and neck squamous cell carcinoma | |
| CN114540499A (zh) | 基于pcd相关基因组合构建的模型在制备预测结肠腺癌预后产品中的应用 | |
| US20200109455A1 (en) | Systems and methods for predicting clinical responses to immunotherapies | |
| JP2023521280A (ja) | 免疫防御応答遺伝子に基づく、前立腺がん対象者のための放射線治療応答の予測 | |
| Li et al. | Lung cancer-associated T cell repertoire as potential biomarker for early detection of stage I lung cancer | |
| Bogusz et al. | Genetic aberrations in small B-cell lymphomas and leukemias: molecular pathology, clinical relevance and therapeutic targets | |
| Abazari et al. | Estimation of survival rates in patients with lung cancer in west Azerbaijan, the northwest of Iran | |
| Aoki et al. | Greater extent of blood‐tumor TCR repertoire overlap is associated with favorable clinical responses to PD‐1 blockade | |
| Li et al. | Prognostic model for risk stratification of de novo metastatic nasopharyngeal carcinoma patients treated with chemotherapy followed by locoregional radiotherapy | |
| Li et al. | Features and efficacy of triple-targeted therapy for patients with EGFR-mutant non-small-cell lung cancer with acquired BRAF alterations who are resistant to epidermal growth factor receptor tyrosine kinase inhibitors | |
| CN105574365A (zh) | 高通量测序突变检测结果的统计学验证方法 | |
| Campo-Le-Brun et al. | Real-world efficacy of immune checkpoint inhibitors in microsatellite unstable/mismatch repair-deficient biliary tract cancer: an AGEO study | |
| Devarakonda et al. | Next-generation sequencing of lung cancers: Lessons learned and future directions | |
| JP2014515477A5 (cg-RX-API-DMAC7.html) | ||
| Thursby et al. | Epigenetic Instability–Based Metrics in Cell-Free DNA for Early Cancer Detection | |
| Guo et al. | Phase II trial of neoadjuvant camrelizumab and apatinib in resectable NSCLC: 3-year survival outcomes and dynamic circulating tumor DNA analyses | |
| Inokuchi et al. | Cadherin 5 is a significant risk factor for hematogenous recurrence and a prognostic factor in locally advanced gastric cancer | |
| Sklodowski et al. | 59 Integrating deep proteomics profiling with survival analysis to identify novel biomarkers of response to PD-1 blockade in NSCLC patients | |
| Luna et al. | 55P CTC count & gene expression profiling among Filipino NSCLC | |
| Potempa-Jeziorowska | Salivary biomarkers for monitoring the course of cancer development–real perspectives | |
| Chen et al. | 169p anlotinib plus chemotherapy as neoadjuvant treatment of high-risk, early-stage triple-negative breast cancer: A prospective, single-arm, single-center, phase ii clinical study |